A gene therapy/targeted radiotherapy strategy for radiation cell kill by

Area of Science:

• Oncology
• Radiotherapy
• Gene Therapy

Background:

• [131I]meta-iodobenzylguanidine (MIBG) is effective for neural crest tumors via noradrenaline transporter (NAT).
• Genetic engineering can introduce NAT into non-NAT expressing tumors, enabling MIBG uptake.
• Previous studies demonstrated MIBG accumulation in NAT-transfected glioblastoma cells.

Purpose of the Study:

• To define conditions for complete tumor cell sterilization using [131I]MIBG in NAT-transfected cells.
• To evaluate the impact of multicellular spheroid culture and radiation crossfire on MIBG efficacy.
• To assess the potential of this gene therapy/targeted radiotherapy approach for broader cancer treatment.

Main Methods:

• NAT-transfected glioblastoma cells (UVW) were cultured as monolayers and multicellular spheroids.
• Cells were treated with varying doses of [131I]MIBG.
• Cell kill was assessed using clonogenic survival assays and spheroid growth delay measurements.
• The effect of radiation crossfire was investigated by varying the time spheroids remained intact post-treatment.

Main Results:

• Complete clonogenic sterilization was achieved with 7 MBq/ml [131I]MIBG in three-dimensional spheroids.
• Prolonging spheroid integrity post-treatment enhanced cell kill via radiation crossfire.
• Spheroid cure was achieved with 6 MBq/ml [131I]MIBG when left intact for 48 hours.
• Cell kill efficiency was significantly influenced by beta-particle crossfire irradiation.

Conclusions:

• [131I]MIBG targeted therapy efficacy is significantly enhanced by beta-particle crossfire in multicellular spheroids.
• This gene therapy combined with targeted radiotherapy strategy shows promise for treating non-neural crest tumors.
• Optimizing MIBG delivery and radiation crossfire can improve therapeutic outcomes in genetically modified tumors.